Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants
Background. Registration of combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in Russia necessitates studies on its preventive efficacy, safety, immunogenic activity, and post-vaccination responses following the immunization of premature infants. Objective. The aim of the study is to...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2024-05-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/2435 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696550560727040 |
|---|---|
| author | Vadislav V. Semerikov Nina O. Yаkobyuk Lyudmila V. Sofronova Nadezhda V. Yuminova Natalia N. Vorobjeva Nikolay A. Kontarov |
| author_facet | Vadislav V. Semerikov Nina O. Yаkobyuk Lyudmila V. Sofronova Nadezhda V. Yuminova Natalia N. Vorobjeva Nikolay A. Kontarov |
| author_sort | Vadislav V. Semerikov |
| collection | DOAJ |
| description | Background. Registration of combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in Russia necessitates studies on its preventive efficacy, safety, immunogenic activity, and post-vaccination responses following the immunization of premature infants. Objective. The aim of the study is to evaluate efficacy, safety, and immunogenic activity of combined trivalent vaccine (measles-rubella-parotitis) and level of post-vaccination responses following the immunization of premature infants. Methods. Experimental studies were conducted to evaluate safety, immunogenicity, and postvaccinal responses after immunization of premature infants with combined within prospective comparative clinical observation. Results. Administration of the combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in premature infants has shown: no cases of measles, rubella or parotitis among vaccinated persons within prospective clinical observation for 2 years; no disturbances in parameters of clinical blood analysis, biochemical blood count, total IgE, IgA, IgM, IgG (immunogram), or urine analysis among vaccinated children over time; no subjective perceptions, adverse events signs at physical examination among vaccinated compared to baseline parameters; low post-vaccination reactions (6.7%) and similar tolerance of trivalent vaccine Vaktrivir among full-term infants (3.3%) (p = 0.301). Conclusion. Administration of the combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in premature infants has demonstrated high safety profile and immunogenic properties for measles, rubella and parotitis components, good tolerability, and low post-vaccination responses after immunization, comparable to vaccination of full-term infants. |
| format | Article |
| id | doaj-art-f203831e5f6a46018c19a5859f3da7b3 |
| institution | DOAJ |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2024-05-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-f203831e5f6a46018c19a5859f3da7b32025-08-20T03:19:25ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892024-05-012129010110.15690/pf.v21i2.27442070Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature InfantsVadislav V. Semerikov0Nina O. Yаkobyuk1Lyudmila V. Sofronova2Nadezhda V. Yuminova3Natalia N. Vorobjeva4Nikolay A. Kontarov5Perm State Pharmaceutical AcademyPerm State Medical University named after Academician E. A. WagnerPerm State Medical University named after Academician E. A. WagnerI. Mechnikov Research Institute of Vaccines and SeraPerm State Medical University named after Academician E. A. WagnerI. Mechnikov Research Institute of Vaccines and SeraBackground. Registration of combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in Russia necessitates studies on its preventive efficacy, safety, immunogenic activity, and post-vaccination responses following the immunization of premature infants. Objective. The aim of the study is to evaluate efficacy, safety, and immunogenic activity of combined trivalent vaccine (measles-rubella-parotitis) and level of post-vaccination responses following the immunization of premature infants. Methods. Experimental studies were conducted to evaluate safety, immunogenicity, and postvaccinal responses after immunization of premature infants with combined within prospective comparative clinical observation. Results. Administration of the combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in premature infants has shown: no cases of measles, rubella or parotitis among vaccinated persons within prospective clinical observation for 2 years; no disturbances in parameters of clinical blood analysis, biochemical blood count, total IgE, IgA, IgM, IgG (immunogram), or urine analysis among vaccinated children over time; no subjective perceptions, adverse events signs at physical examination among vaccinated compared to baseline parameters; low post-vaccination reactions (6.7%) and similar tolerance of trivalent vaccine Vaktrivir among full-term infants (3.3%) (p = 0.301). Conclusion. Administration of the combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in premature infants has demonstrated high safety profile and immunogenic properties for measles, rubella and parotitis components, good tolerability, and low post-vaccination responses after immunization, comparable to vaccination of full-term infants.https://www.pedpharma.ru/jour/article/view/2435measlesrubellamumpschildrensafetyimmunogenicity |
| spellingShingle | Vadislav V. Semerikov Nina O. Yаkobyuk Lyudmila V. Sofronova Nadezhda V. Yuminova Natalia N. Vorobjeva Nikolay A. Kontarov Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants Педиатрическая фармакология measles rubella mumps children safety immunogenicity |
| title | Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants |
| title_full | Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants |
| title_fullStr | Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants |
| title_full_unstemmed | Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants |
| title_short | Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants |
| title_sort | preventive efficacy safety immunogenic activity and evaluation of post vaccination responses following immunization with combined trivalent vaccine vaktrivir measles rubella parotitis in premature infants |
| topic | measles rubella mumps children safety immunogenicity |
| url | https://www.pedpharma.ru/jour/article/view/2435 |
| work_keys_str_mv | AT vadislavvsemerikov preventiveefficacysafetyimmunogenicactivityandevaluationofpostvaccinationresponsesfollowingimmunizationwithcombinedtrivalentvaccinevaktrivirmeaslesrubellaparotitisinprematureinfants AT ninaoyakobyuk preventiveefficacysafetyimmunogenicactivityandevaluationofpostvaccinationresponsesfollowingimmunizationwithcombinedtrivalentvaccinevaktrivirmeaslesrubellaparotitisinprematureinfants AT lyudmilavsofronova preventiveefficacysafetyimmunogenicactivityandevaluationofpostvaccinationresponsesfollowingimmunizationwithcombinedtrivalentvaccinevaktrivirmeaslesrubellaparotitisinprematureinfants AT nadezhdavyuminova preventiveefficacysafetyimmunogenicactivityandevaluationofpostvaccinationresponsesfollowingimmunizationwithcombinedtrivalentvaccinevaktrivirmeaslesrubellaparotitisinprematureinfants AT natalianvorobjeva preventiveefficacysafetyimmunogenicactivityandevaluationofpostvaccinationresponsesfollowingimmunizationwithcombinedtrivalentvaccinevaktrivirmeaslesrubellaparotitisinprematureinfants AT nikolayakontarov preventiveefficacysafetyimmunogenicactivityandevaluationofpostvaccinationresponsesfollowingimmunizationwithcombinedtrivalentvaccinevaktrivirmeaslesrubellaparotitisinprematureinfants |